

Vision

Empowered by movement, people with spinal cord injury will enjoy life in every way that matters to them

Key Facts

- Founded in 2014 by researchers at EPFL, Lausanne, including neuroscientist Prof. Grégoire Courtine and neurosurgeon Jocelyne Bloch
- Headquartered in The Netherlands with science and research hub in Switzerland and growing presence in the USA
- Led by an experienced and international management team
- Raised EUR 73M in private funding since inception
- Backed by major life science investors and leading patient associations.
- ARC Therapy is targeted, programmed electrical stimulation of the spinal cord
- Therapy is delivered via implantable platform (called ARC^{IM}) or external platform (called ARC^{EX}).
- Received Three FDA Breakthrough Device Designations providing streamlined path to regulatory approval in the U.S.
- Potential to treat other indications, e.g. stroke and Parkinson's disease
- Strong and growing IP portfolio, over 290 issued or pending patents worldwide

Spinal Cord Injury

Damage to the spinal cord results in loss of function


The spinal segment level of a spinal cord injury (SCI) determines which body functions are impacted, while the lesion severity indicates the extent to which those functions are affected

People with SCI suffer from:

- Paralysis
- Loss of sensation
- Other complications, e.g. poor blood pressure regulation, urinary and/or fecal incontinence, spasticity and poor quality of life

There is no cure for SCI

Few therapies exist to improve strength & function in people with SCI



Large & Underserved Market



¹ 2020 NSCISC Annual Statistical Report Complete Public Version

² European prevalence calculated by annual Incidence* 25 years of additional lifetime expectancy

³ Kumar et al. 2018, Traumatic Spinal Injury: Global Epidemiology and Worldwide Volume (traumatic spinal injury may be broader than traumatic spinal cord injury).

ONWARD ARC™ Therapy

Targeted, programmed electrical stimulation of the spinal cord to restore movement, independence, and health in people with spinal cord injury

ARC Therapy is delivered through two highly synergistic platforms ARC^{EX} and ARC^{IM} which share common components, hardware, and software systems

ARC^{EX}




Smart Watch



Stimulator



Programmer



Electrodes & Leads

- External system for non-invasive, programmed stimulation of the spinal cord using proprietary frequency
- FDA Breakthrough Device Designation for Upper Limbs received in October 2017
- Up-LIFT pivotal study to evaluate the safety and effectiveness of ARC^{EX} Therapy in restoring hand and arm function in people with SCI started in January 2021
- Regulatory clearance expected in early 2023 for restoration of upper extremity strength and function
- Plan to explore additional indications in the future

ARC^{IM}



Smart Watch



Stimulator



Programmer



Lead



IPG

- Implantable platform consisting of IPG and leads for direct, programmed stimulation of the spinal cord
- Potential to address several indications, for example:
 - Arm and hand function (1)
 - Blood pressure and trunk control (2)
 - Mobility (walking and standing) (3)
 - Bladder and bowel control (4)
- FDA Breakthrough Device Designation received for:
 - Blood pressure and trunk control, June 2021
 - Mobility, May 2020
- Regulatory approvals expected in:
 - 2024 for Blood pressure and trunk control
 - 2025 for Mobility

